BFM
XENE icon

Boothbay Fund Management’s Xenon Pharmaceuticals XENE Stock Holding History

Boothbay Fund Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.7M Buy
270,412
+234,731
+658% +$10.8M 0.2% 62
2025
Q4 		$1.6M Buy
35,681
+6,822
+24% +$287K 0.02% 651
2025
Q3 		$1.16M Buy
+28,859
New +$1.02M 0.02% 771
2025
Q1 		– Sell
-17,395
Closed -$682K – 1833
2024
Q4 		$682K Sell
17,395
-12,750
-42% -$527K 0.02% 770
2024
Q3 		$1.19M Hold
30,145
– – 0.03% 701
2024
Q2 		$1.18M Sell
30,145
-216
-0.7% -$8.63K 0.03% 665
2024
Q1 		$1.31M Sell
30,361
-9,895
-25% -$455K 0.03% 657
2023
Q4 		$1.85M Buy
+40,256
New +$1.42M 0.05% 522
2023
Q3 		– Sell
-9,983
Closed -$384K – 2121
2023
Q2 		$384K Sell
9,983
-1,842
-16% -$73.2K 0.01% 1210
2023
Q1 		$423K Hold
11,825
– – 0.01% 1322
2022
Q4 		$466K Hold
11,825
– – 0.01% 1201
2022
Q3 		$427K Sell
11,825
-14,481
-55% -$521K 0.01% 1313
2022
Q2 		$800K Buy
26,306
+1,980
+8% +$59.9K 0.02% 926
2022
Q1 		$744K Buy
24,326
+5,950
+32% +$178K 0.02% 1087
2021
Q4 		$574K Sell
18,376
-32,948
-64% -$985K 0.01% 958
2021
Q3 		$784K Sell
51,324
-44,433
-46% -$772K 0.02% 877
2021
Q2 		$1.78M Buy
95,757
+4,941
+5% +$91.1K 0.06% 427
2021
Q1 		$1.63M Buy
90,816
+48,303
+114% +$819K 0.06% 392
2020
Q4 		$654K Buy
42,513
+5,995
+16% +$70.1K 0.02% 654
2020
Q3 		$404K Sell
36,518
-8,167
-18% -$96.1K 0.02% 722
2020
Q2 		$560K Sell
44,685
-20,304
-31% -$258K 0.04% 545
2020
Q1 		$737K Buy
64,989
+13,982
+27% +$199K 0.06% 369
2019
Q4 		$669K Hold
51,007
– – 0.06% 414
2019
Q3 		$460K Sell
51,007
-765
-1% -$7.23K 0.04% 479
2019
Q2 		$510K Sell
51,772
-22,390
-30% -$214K 0.05% 407
2019
Q1 		$753K Buy
74,162
+39,480
+114% +$335K 0.07% 295
2018
Q4 		$219K Buy
34,682
+15,407
+80% +$137K 0.03% 473
2018
Q3 		$254K Sell
19,275
-16,044
-45% -$186K 0.03% 564
2018
Q2 		$325K Buy
+35,319
New +$219K 0.03% 452

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Boothbay Fund Management's XENE Position: Q1 2026 in Review

Boothbay Fund Management increased its Xenon Pharmaceuticals (XENE) stake by 658% in Q1 2026, buying an estimated $10.8M and bringing the position to 270,412 shares worth $15.7M. The position accounts for 0.2% of the portfolio, ranked #62.

Boothbay Fund Management first reported a position in XENE in Q2 2018 and has held it in 29 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Boothbay Fund Management held 270,412 shares of Xenon Pharmaceuticals worth $15.7M as of Q1 2026.
  • Boothbay Fund Management bought 234,731 Xenon Pharmaceuticals shares in Q1 2026, an estimated $10.8M.
  • Xenon Pharmaceuticals made up 0.2% of Boothbay Fund Management's portfolio in Q1 2026, its #62 holding.
  • Boothbay Fund Management first reported a position in Xenon Pharmaceuticals in Q2 2018 and has held it in 29 quarters since.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.